Tolinapant induces durable regressions in an in vivo syngeneic model of TCL. (A) Mice bearing ∼100 mm³ HH tumors were treated with vehicle or with 20 mg/kg tolinapant (daily oral for 18 days). Error bars, mean ± standard error of the mean (SEM). n = 10 per group. Two-way analysis of variance (ANOVA): **P < .01. (B) Mice bearing ∼100 mm³ SUP-T1 tumors were treated with vehicle or with 20 mg/kg tolinapant (daily oral for 9 days). Error bars, mean ± SEM. n = 8 per group. Two-way ANOVA: *P < .05. (C) Mice bearing HH xenograft tumors received a single oral dose of tolinapant at 25 mg/kg. Animals were sacrificed at the indicated time points, and protein levels in tumors were measured by immunoblotting of whole-tumor lysates. Each sample represents individual tumors. (D) Mice bearing ∼50 mm³ BW5147 tumors were treated with vehicle or with 25 mg/kg tolinapant (daily oral). Error bars, mean ± SEM. n = 10 per group. (E) Individual BW5147 tumor volume plots from mice treated with vehicle (top) or 25 mg/kg tolinapant (bottom) (n = 10 per group). (F) Mice bearing BW5147 tumors received a single oral dose of tolinapant at 25 mg/kg. Animals were euthanized at the indicated time points, and protein levels in tumors were measured by immunoblotting of whole-tumor lysates. Each sample represents individual tumors.